• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Alzinova

0.55 SEK

+0.55 %

Less than 1K followers

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.55 %
+13.54 %
-7.47 %
-34.26 %
-33.54 %
-66.44 %
-77.57 %
-90.46 %
-92.40 %

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.

Read more
Market cap
110.44M SEK
Turnover
632.44K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.8
2026

Interim report Q2'26

12.11
2026

Interim report Q3'26

25.2
2027

Annual report '26

Press release24.06.2026, 17.37

DNB Carnegie Access: Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds

Alzinova
Regulatory press release24.06.2026, 09.00

Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test

Alzinova
Regulatory press release12.06.2026, 07.30

Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million

Alzinova

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release08.06.2026, 16.48

Alzinova announces preliminary outcome of the exercise of warrants of series TO4

Alzinova
Regulatory press release03.06.2026, 08.30

The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026

Alzinova
Regulatory press release26.05.2026, 16.16

Bulletin from the Annual General Meeting of Alzinova AB (publ)

Alzinova
Regulatory press release25.05.2026, 08.30

The subscription price for warrants of series TO4 in Alzinova has been determined to SEK 0.32 and the exercise period begins today

Alzinova
Regulatory press release21.05.2026, 10.35

Alzinova has received subscription commitments and underwriting commitments corresponding to 80 percent of the exercise of warrants of series TO4

Alzinova
Regulatory press release20.05.2026, 10.23

Alzinova’s clinical results with ALZ-101 now published in Alzheimer’s Research & Therapy

Alzinova
Press release13.05.2026, 15.18

Redeye: Alzinova (Q1 Review): Scientific validation and strategic optionality

Alzinova
Regulatory press release13.05.2026, 08.42

Correction: Alzinova publishes interim report for the period January – March 2026

Alzinova
Regulatory press release13.05.2026, 07.30

Alzinova publishes interim report for the period January – March 2026

Alzinova
Regulatory press release12.05.2026, 10.36

Interview with Dr. Marwan Sabbagh – why ALZ-101 represents a next-generation approach in Alzheimer’s Disease

Alzinova
Regulatory press release11.05.2026, 15.06

Alzinova’s clinical results with ALZ-101 to be published in scientific journal

Alzinova
Regulatory press release30.04.2026, 10.58

Alzinova changes the date of its interim report Q1

Alzinova
Regulatory press release23.04.2026, 08.30

Alzinova publishes annual report for 2025

Alzinova
Regulatory press release22.04.2026, 19.30

NOTICE OF ANNUAL GENERAL MEETING IN ALZINOVA AB (PUBL)

Alzinova
Regulatory press release08.04.2026, 09.17

Alzinova initiates collaboration with Amsterdam UMC to develop blood-based Alzheimer’s diagnostic test

Alzinova
Press release25.03.2026, 17.53

DNB Carnegie Access: Alzinova: Cash secured, but execution remains key – Q4 review

Alzinova
Press release25.03.2026, 16.45

Redeye: Alzinova (Q4 Review): Extended runway, still focus on deal

Alzinova